This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

Restrictions on gabapentinoids causing 'fear and anxiety' among patients

Reclassifying pregabalin and gabapentin as controlled drugs is creating ‘fear and anxiety’ among the patients who use them responsibly, a charity has said.

Pain Concern, a Scotland-based health charity, said the circumstances surrounding the rise in the number of deaths associated with the drugs ‘haven’t been properly examined’. 

This comes after official figures revealed last month that there were 111 deaths related to pregabalin in 2016 and 59 related to gabapentin, compared with four and eight respectively in 2012.

As a result, the Government announced that it had accepted recommendations from advisers to make them a class C drug, subject to a consultation.

In June. BMA leaders called for pregabalin to be reclassifyed as a controlled drug following evidence it is increasingly used recreationally and in prison populations.

Following the Government's announcement, Dr Andrew Green, clinical and prescribing policy lead for the BMA’s GP Committee, welcomed the change in legislation, saying the drugs ‘have a significant potential for dependence’.

But Heather Wallace, chair of Pain Concern, said the people who are not misusing the drugs ‘feel they are being punished for something they haven’t done’.

She said: ‘In many cases it is difficult to find the right combination of pain relief, and we know from our helpline that people have been left fearful and confused by this proposal and all the publicity it has generated.

‘It’s premature and risks harming people who are using these medicines because there is nothing else for them that works’.

However, several studies have warned GPs against prescribing the two drugs.

A Cochrane Review from June this year found that gabapentin ‘can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy’, but added that its effectiveness for other types of neuropathic pain ‘is very limited’. 

Meanwhile, another study published in Addiction last year, that found that misuse of gabapentin was at a staggering ‘40-65% among individuals with prescriptions’.

GPs have previously been told by NHS England to prescribe Lyrica, and not pregabalin, for neuropathic pain – a decision which was later overturned by a High Court decision.

Readers' comments (5)

  • "Fear and anxiety"......cardinal symptoms of the abstinence syndrome???

    Unsuitable or offensive? Report this comment

  • I say, give them jobs that pay well and workplaces devoid of discrimination. Give them well built and insulated houses and help them find spouses that don't abuse them. Give their children schools with outstanding performance and free of bullying and any other form of abuse. Give them income that makes decent living and stop building unrealistic expectations through do-gooder charities and commercial interests campaigns... and they just might like the reality they live in and stop trying to augment it biochemically. Which might mean stopping using local GP as drug dealer..

    Unsuitable or offensive? Report this comment

  • Rogue1

    Given the new safety warnings surrounding the group, it is only right to prescribe them in a safer (CD) way. Patients that understand that and are using them for pain, wont really object. Others that are getting other 'benefits' from them may well do and their true colours will show.

    Unsuitable or offensive? Report this comment

  • This comment has been deleted

    Unsuitable or offensive? Report this comment

  • AlanAlmond

    I’m gobsmacked
    Restricting a drug used, amongst other things, for generalised anxiety disorder and crap life syndrome is causing anxiety and exacerbating crap lives
    Well I never

    Unsuitable or offensive? Report this comment

Have your say